in vitro News and Research

RSS

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.

19 Oct 2009

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA.

19 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

ADI and CeTeCancer collaborate for research project

Radient Pharmaceuticals Corporation, a US-based pharmaceutical company, announced today it has entered into a collaboration agreement through its wholly owned subsidiary AMDL Diagnostics, Inc. (ADI) with CeTeCancer -- a Chilean-based research laboratory -- to validate the effectiveness of Radient Pharmaceuticals' Onko-Sure™ in vitro diagnostic (IVD) cancer test as an early detection and prevention test for lung cancer.

15 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

DNA authentication technology to distinguish between in-vivo and in-vitro DNA

Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced that company researchers today presented its DNA authentication technology, a novel assay to distinguish between in-vivo (real) and in-vitro (fake) DNA, at the 20th International Symposium on Human Identification in Las Vegas, Nevada.

15 Oct 2009

Harvard researchers unite in fight against antibiotic resistance

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard researchers to launch the "Harvard-wide Program on Antibiotic Resistance."

14 Oct 2009

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

14 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Diagnostics industry in Asia Pacific poised to present more growth opportunities

The global diagnostics industry has witnessed strong growth over the past few years. According to Frost & Sullivan, the diagnostics and monitoring sectors are poised to present more growth opportunities. According to Nitin Naik, Vice President of Frost & Sullivan's Asia Pacific Medical Technologies Division, the diagnostics and monitoring sectors in Asia Pacific are projected to provide more growth opportunities on the basis of the technology spending being channelled in these areas (80 percent).

13 Oct 2009

Melanocyte-like cells in heart and pulmonary veins contribute to atrial fibrillation

The source and mechanisms underlying the abnormal heart beats that initiate atrial fibrillation (Afib), the most common type of abnormal heart beat, have not been well determined. However, a group of researchers at the University of Pennsylvania, Philadelphia, has now identified a population of cells that are like pigment producing cells in the skin (melanocytes) in the atria of the heart and pulmonary veins of mice and humans and uncovered evidence in mice that these cells contribute to Afib.

13 Oct 2009

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

According to new research from the Monell Center and the Mount Sinai School of Medicine, certain common herbicides and lipid-lowering fibrate drugs act in humans to block T1R3, a nutrient-sensing taste receptor also present in intestine and pancreas.

12 Oct 2009

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

New findings highlight potential role of copper in Alzheimer's disease

New research has shown that there could be a protective role for copper in Alzheimer's disease.

9 Oct 2009

Medical tourism in Latin America requires regulation: University of Montreal researchers

Medical tourism in Latin America needs to be regulated to protect consumers, according to Universit- de Montr-al researchers. A new study published in the journal Developing World Bioethics argues that Argentinean fertility clinics are increasingly marketing themselves to international health care consumers: these clinics offer all-inclusive packages with fixed prices that feature airfare, accommodations, transfers, language interpreters and, of course, fertility treatments.

8 Oct 2009

The CE Marked HairDX Genetic Test for Hair Loss launched in Europe

The HairDX Genetic Test for Hair Loss, the world’s first genetic baldness (Androgenetic Alopecia) test, is now available as a CE Marked product under the European In Vitro Diagnostic Directive.

8 Oct 2009

Scientists make significant advance towards a solution for neuronal repair

The repair of damaged nerve cells is a major problem in medicine today. A new study by researchers at the Montreal NeurologicaI Institute and Hospital (The Neuro) and McGill University, is a significant advance towards a solution for neuronal repair.

8 Oct 2009

Late-onset sepsis in very low birth-weight newborns may be prevented with supplemental milk protein

Very low birth-weight newborns who received the milk protein lactoferrin alone or in combination with a probiotic had a reduced incidence of late-onset sepsis, according to a study in the October 7 issue of JAMA.

7 Oct 2009

GTRI researchers to test the affect of RFID systems on implantable and wearable medical devices

Radio frequency identification (RFID) systems are widely used for applications that include inventory management, package tracking, toll collection, passport identification and airport luggage security. More recently, these systems have found their way into medical environments to track patients, equipment assets and staff members.

7 Oct 2009

in vitro News and Research

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Fate Therapeutics announces human iPSC generation using a combination of small molecules

ADI and CeTeCancer collaborate for research project

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

DNA authentication technology to distinguish between in-vivo and in-vitro DNA

Harvard researchers unite in fight against antibiotic resistance

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Sequella receives Phase 1 SBIR grant for developing SQ641

Diagnostics industry in Asia Pacific poised to present more growth opportunities

Melanocyte-like cells in heart and pulmonary veins contribute to atrial fibrillation

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Presentations on efficacy of interferon to combat influenza

New findings highlight potential role of copper in Alzheimer's disease

Medical tourism in Latin America requires regulation: University of Montreal researchers

The CE Marked HairDX Genetic Test for Hair Loss launched in Europe

Scientists make significant advance towards a solution for neuronal repair

Late-onset sepsis in very low birth-weight newborns may be prevented with supplemental milk protein

GTRI researchers to test the affect of RFID systems on implantable and wearable medical devices

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News